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Patients with autoimmune conditions develop lymphoproliferative disorders (LPDs) at a higher frequency than normal both in
association with and independent of Methotrexate (MTX). We describe a case of MTX-associated lymphoma in a patient with
psoriasis on long-standing MTX. The case is notable for the initial tumor burden, the dramatic disappearance of the PET-CT
ﬁndings on discontinuation of MTX, and the subsequent early regrowth of disease. Our case report is illustrative of an MTX-
relatedNHLinanautoimmunepatient.Conclusion.WithdrawalofMTXinapatientwithlymphomaisreasonablebeforeinitiating
chemotherapy, but observation for early regrowth of disease is necessary.
Copyright © 2009 Rachel C. Jankowitz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Patients with autoimmune and inﬂammatory disorders
develop lymphoproliferative disorders (LPDs) at a higher
frequency than the normal population [1]. Immune dys-
regulation, both hyperimmunity and/or immunodeﬁciency,
may underlie such LPD [2]. Rheumatoid arthritis (RA)
patients have an approximately twofold increase in incidence
of lymphoma [2], and patients with severe psoriasis have a
modestly increased incidence of lymphoma: 7.9/100,000 per
year [3].
Methotrexate (MTX) is an antimetabolite and immuno-
suppressant used in the treatment of autoimmune con-
ditions. Its mechanism of predisposing patients to LPD
is unclear [4], as patients with autoimmune conditions
develop LPD both in association with and independent of
MTX administration. The association between MTX and
lymphoma was ﬁrst reported in a patient on weekly oral
pulse-methotrexate in 1993 [5], and now numerous case
studies have reported similar ﬁndings [6–16]. It has been
suggested that the disease state of RA, not speciﬁc therapy,
underlies the development of lymphoma in RA patients [2,
17]. Cases of MTX-related lymphomas are often extranodal
in origin, are often EBV-associated [7], and can respond to
withdrawal of immunosuppression [18].
We describe a case of MTX-associated LPD in a patient
with longstanding, severe psoriasis. The remarkable features
of this case include the tumor burden at presentation, the
rapidanddramaticdisappearanceofthePET-CTﬁndingson
discontinuationofMTX,andthesubsequentearlyre-growth
of disease.
The patient is a 70-year-old gentleman with a history
of Hepatitis B exposure, chronic obstructive pulmonary
disease (COPD), coronary artery disease, hypertension, and
psoriasistreatedwithMTXfortwoyears.Hehadbeentaking
a 20mg weekly dose of MTX and had never been treated
with any other immunosuppressive agents. Three weeks
prior to presenting at our clinic, he stopped MTX due to
deteriorating health. For two months, he had poor appetite,
early satiety, and alternating diarrhea and constipation. He
hadintermittentcrampyabdominalpain,a20-poundweight
loss, fatigue, and occasional night sweats without fever or2 Case Reports in Medicine
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Figure 1: Imaging Test Results: images from 3 diﬀerent PET/CT scans are shown above. Images from the patient’s initial study are on the left
and show extensive abnormal areas of FDG activity on the coronal PET image and correlative CT and fused PET/CT images (inset left) of
the large lesion in the liver. A second scan performed 30 days after the baseline scan shows complete resolution of the abnormal FDG activity
(middle group of images) in all lesions after discontinuation of the patient’s methotrexate. No other treatment was initiated. Note persistent
low attenuation lesion in the liver (inset middle). Image on the right from a repeat scan 90 days later shows multiple new lesions, most of
which were not even present on the initial scan.
pruritus. Physical exam revealed an elderly gentleman who
appeared depressed and fatigued. He was afebrile. His blood
pressurewas104/58,hisheartratewas62,andhisrespiratory
rate was 14. His skin showed no active psoriatic lesions, and
he had no palpable peripheral lymphadenopathy. Head and
neck exam revealed no jaundice, and a clear oral pharynx.
Heart and lung exams were normal. He had a protuberant
abdomen with a tender palpable liver that extended below
the xiphoid. There was no ascites or splenomegaly.
WBC count was 8.9 × 109/L with normal diﬀerential,
hemoglobin was 12.3g/dL, and platelet count was 347 ×
109/L. LDH was 667IU/L (nl. range 313–618IU/L), alkaline
phosphatase was 198IU/L (nl. range 38–126IU/L); and
SGOT and ALT were normal. CEA was <0.5ng/mL, and AFP
was 3ng/mL. Colonoscopy was negative.
Initial PET/CT scan (Figure 1) showed widespread FDG-
avid lymphadenopathy in the neck, axillae, upper abdomen,
retroperitoneum, pelvis, and inguinal regions. Extensive
bony abnormalities were present in the thorax, spine, and
pelvis.MultipleFDG-avidlesionswereintheliver;thelargest
measured 8.9 cm.
Liver biopsy by Fine Needle Aspiration (FNA) 1 week
after presentation showed atypical spindly cells in a back-
ground of lymphoid cells with severe crush artifact and was
nondiagnostic for tumor. Repeat core liver biopsy (Figure 2)
was also negative for malignant cells, showing a lymphoid
inﬁltrate that lacked cytologic atypia. Immunostains showed
predominantly CD3+ T cells with very rare CD20+ small B
cells; EBV-encoded RNA in situ hybridization (EBER ISH)
wasnegative(Figures2(a)–2(d)).MolecularstudiesforTcell
receptor gene rearrangement by PCR analysis were
negative.
Bone marrow biopsy 3 weeks after presentation showed
no evidence of neoplasm and normal cytogenetics. FNA of
an inguinal lymph node the next day was also nondiagnostic
a n dd e v o i do fl y m p h o i dt i s s u e .
PET/CT scan that was repeated at one month (Figure 1)
and oﬀ MTX for 7 weeks showed dramatic decrease in
all areas of lymphadenopathy, with complete resolution of
abnormal FDG-uptake in his liver, bone, and lymph nodes.
The patient felt much better, had gained 6 pounds of weight,
and denied B-symptoms or abdominal pain.
Unfortunately, repeating PET/CT three months later
(Figure 1) showed interval progression of disease with new
onset of conglomerate lymphadenopathy in multiple lymph
node regions as well as a new enhancing lesion near the
head of the pancreas, a soft tissue nodule inferior to the
right hepatic lobe, and new-onset hypermetabolic lesions
involving the right and left iliac bones.
Abiopsyoftherightaxillarylymphnodeshowedreactive
c h a n g e sa sw e l la saf o c a lc l u s t e ro fa b n o r m a lf o l l i c l e s
lacking polarization with numerous large cells. Immunos-
tains showed that the large cells were BCL6+ BCL2−,a n d
conﬁrmed intact, although focally eﬀaced, CD21+ follicular
dendritic meshworks (Figures 2(e)–2(h)). EBER ISH was
negative. Cytogenetic studies revealed a clonal population
with multiple karyotypic abnormalities, including involve-
ment of the immunoglobulin heavy chain gene (14q32),
and supported involvement by B cell lymphoma. Molecular
studies were negative for clonal T and B cell rearrangements.
Laparoscopic-guided retroperitoneal biopsy of the juxta-
gastric lymph node was performed and established the
diagnosis of B cell lymphoma, large cell type. Histologic
sections demonstrated a diﬀuse inﬁltrate comprised ofCase Reports in Medicine 3
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Figure 2: Pathology: (a) H and E section of liver core biopsy with dense inﬁltrate of small lymphocytes, original magniﬁcation 100X. (b)
CD3 immunostain showing predominance of small T cells, original magniﬁcation 400X. (c) CD20 immunostain showing rare positive small
B cells (arrows), original magniﬁcation 400X. (d) EBV encoded RNA in-situ hybridization (EBER), original magniﬁcation 400X. (e) H and
E section of right axillary lymph node showing cluster of abnormal follicles, original magniﬁcation 100X. (f) CD21 immunostain showing
intact but focally eﬀaced follicular dendritic meshworks, original magniﬁcation 100X. (g) BCL6 immunostain showing many positive cells
in follicles, original magniﬁcation 100X. (h) BCL2 immunostain with numerous negative cells in follicles, original magniﬁcation 100X. (i)
H and E section of juxta-gastric lymph node demonstrating diﬀuse inﬁltrate of histiocytes and small and large lymphoid cells, original
magniﬁcation 100X. (j) CD20 immunostain highlighting large lymphoid cells within inﬁltrate, original magniﬁcation 400X. (k) BCL6
immunostain showing scattered positive cells, including large lymphoid cells, original magniﬁcation 400X. (l) EBV encoded RNA in-situ
hybridization (EBER), original magniﬁcation 100X.
large CD20 positive B lymphoid cells in a background of
histiocytes and small lymphocytes, scattered BCL6+ large
lymphoid cells, and EBER ISH was negative (Figures 2(i)–
2(l)). The proliferation index was 30%, as highlighted
by Ki-67 immunostaining. In the diﬀuse areas, underly-
ing CD21+ follicular dendritic cell meshworks were not
identiﬁed. However follicular dendritic meshworks were
identiﬁed in a few BCL6+ BCL2+ nodules of large cells,
reminiscent of the prior right axillary lymph node speci-
men. Although no metaphases were obtained for classical
cytogenetic studies, FISH studies performed on paraﬃn-
embedded tissue on both nodal specimens showed similar
results and were positive for an Immunoglobulin heavy
locus (IGH) rearrangement and negative for rearrangements
of the MYC, BCL6, BCL2, and BCL3 loci. The ﬁndings
suggested a similar pathologic process in both specimens,
with likely focal follicular colonization in the prior right
axillary lymph node specimen by large cell lymphoma in
light of the pathologic features from the juxta-gastric lymph
node.
Treatment was initiated with standard doses of
Cyclophosphamide, Adriamycin, Vincristine, Prednisone,
and Rituximab (CHOP-R).
Patients with autoimmune and chronic inﬂammatory
disorders develop lymphoma at a higher frequency than
the normal population [7]. It is unclear why such rela-
tively hyperimmune patients are predisposed to lymphoma.
Chronic antigen stimulation by exogenous or endogenous
antigens such as viruses or bacteria, in the setting of
chronic inﬂammation and decreased immune surveillance,
is hypothesized to underlie the transformation of B-cells
to malignant clones [2]. While such antigenic stimulation
drives B-cell immunoglobulin gene rearrangement, con-
stitutive oncogenic expression may occur, with resultant
uncontrolled clonal proliferation of B-cells [2].
EBV normally causes asymptomatic primary infection of
B-cells, but it does occasionally fuel a malignant transfor-
mation process, particularly in germinal-center B-cells [19].
CasesofMTX-relatedLPDsareoftenEBV-associated[7]and
may respond to simple withdrawal of immunosuppression4 Case Reports in Medicine
[18] suggesting that restoration of normal immunity may
suppress EBV-related lymphomas. Feng studied the eﬀect of
MTX and other immunosuppressants on EBV replication in
vitro and found that it activated the release of infectious EBV
from latently infected cell lines and that patients treated with
MTX had higher blood-levels of EBV than those on other
immunosuppressives [20].
Despite the association of MTX-related LPDs and EBV-
positivity, our EBV-negative patient showed dramatic reduc-
tion in disease burden with resolution of abnormal FDG-
uptake on PET/CT after withdrawal of MTX as can be seen
in Figure 1. Similarly, in a Japanese study of 76 RA patients
with LPD [6], those treated with MTX developed LPDs in a
shorter period of time than those who were not on the drug.
After withdrawal of MTX, spontaneous regression of masses
occurred in 11 of the 48 cases and continued for 8 to 64
months. Six of the 11 cases responding to MTX withdrawal
were EBV-positive, but 5 were EBV-negative like our patient.
Three out of 5 cases that had recurrence of LPD after initial
response to MTX withdrawal were EBV-negative. The higher
recurrence rate in the EBV-negative LPD group may have
been related to their underlying autoimmune disease and/or
an inability to control chronic inﬂammation.
Unfortunately, our patient also experienced a short
disease-free interval of only 2 months in response to MTX
withdrawal. Biopsy at the time of recurrence was diagnostic
of a malignant lymphoma, large B cell type, which was EBV-
negative. We can only speculate that at presentation, the
patient may have had an EBV-positive B-cell lymphoma with
complete lysis of the EBV-positive clones as the MTX was
withdrawn. Alternatively, our patient may represent a case of
EBV-negative MTX-related lymphoma with rapid but short-
lived regression upon withdrawal of MTX.
Our report is illustrative of an MTX-related NHL in
a patient with a chronic inﬂammatory state treated with
immunosuppressive therapy. It was striking in this case
how diﬃcult it was to make a tissue diagnosis despite
the markedly abnormal PET/CT. There was very rapid
improvement in his scans after MTX withdrawal, only to
be followed by regrowth of disease within 2 months. Based
on this case and others in literature, we suggest withdrawal
of MTX in any patient diagnosed or suspected of having
lymphoma before initiation of systemic chemotherapy, even
incaseswithﬂoriddisease.However,closeinitialobservation
for early regrowth of disease even in responding patients is
warranted.
References
[1] L. A. Anderson, S. Gadalla, L. M. Morton, et al., “Population-
based study of autoimmune conditions and the risk of speciﬁc
lymphoid malignancies,” International Journal of Cancer, vol.
125, no. 2, pp. 398–405, 2009.
[2] G. Starkebaum, “Rheumatoid arthritis and lymphoma: risky
business for B cells,” Journal of Rheumatology, vol. 34, no. 2,
pp. 243–246, 2007.
[3] J. M. Gelfand, D. B. Shin, A. L. Neimann, X. Wang, D. J.
Margolis, and A. B. Troxel, “The risk of lymphoma in patients
with psoriasis,” Journal of Investigative Dermatology, vol. 126,
no. 10, pp. 2194–2201, 2006.
[4] G. Starkebaum, “Rheumatoid arthritis, methotrexate, and
lymphoma: risk substitution, or cat and mouse with Epstein-
Barrvirus?”JournalofRheumatology,vol.28,no.12,pp.2573–
2575, 2001.
[5] M. H. Ellman, H. Hurwitz, C. Thomas, and M. Kozloﬀ,
“Lymphoma developing in a patient with rheumatoid arthritis
taking low dose weekly methotrexate,” Journal of Rheumatol-
ogy, vol. 18, no. 11, pp. 1741–1743, 1991.
[6] Y. Hoshida, J.-X. Xu, S. Fujita, et al., “Lymphoproliferative
disorders in rheumatoid arthritis: clinicopathological analysis
of 76 cases in relation to methotrexate medication,” Journal of
Rheumatology, vol. 34, no. 2, pp. 322–331, 2007.
[ 7 ]O .W .K a m e l ,M .v a nd eR i j n ,D .P .L e B r u n ,L .M .W e i s s ,
R. A. Warnke, and R. F. Dorfman, “Lymphoid neoplasms
in patients with rheumatoid arthritis and dermatomyositis:
frequency of Epstein-Barr virus and other features associated
with immunosuppression,” Human Pathology, vol. 25, no. 7,
pp. 638–643, 1994.
[8] O. W. Kamel, M. van de Rijn, L. M. Weiss, et al., “Brief
report: reversible lymphomas associated with Epstein-Barr
virus occurring during methotrexate therapy for rheumatoid
arthritis and dermatomyositis,” The New England Journal of
Medicine, vol. 328, no. 18, pp. 1317–1321, 1993.
[9] J.W.Kennedy,L.K.Wong,B.Kalantarian,L.Turner,andC.W.
Hayes, “An unusual presentation of methotrexate-induced B-
cell lymphoma of the metacarpophalangeal joint: a case report
andliteraturereview,”TheJournalofHandSurgery,vol.31,no.
7, pp. 1193–1196, 2006.
[10] H. Kono, S. Inokuma, Y. Matsuzaki, et al., “Two cases of
methotrexate induced lymphomas in rheumatoid arthritis: an
association with increased serum IgE,” Journal of Rheumatol-
ogy, vol. 26, no. 10, pp. 2249–2253, 1999.
[11] G. C. Mackie and J. M. Pohlen, “Methotrexate-induced pul-
monary non-Hodgkin lymphoma,” Clinical Nuclear Medicine,
vol. 31, no. 5, pp. 272–274, 2006.
[ 1 2 ]S .H .N a s r ,B .A l o b e i d ,J .M .J a c o b s ,T .E .P e a c o c k ,V .D .
D’Agati,andG.S.Markowitz,“Methotrexate-associatedB-cell
lymphoma presenting with acute renal failure and bilateral
nephromegaly,” Kidney International, vol. 71, no. 3, pp. 272–
275, 2007.
[ 1 3 ] B .D .N g u y e n ,M .C .R o a r k e ,a n dA .E .M c C u l l o u g h ,
“Methotrexate-induced and Epstein-Barr virus-associated B-
cell lymphoma of the spine: MR and PET/CT imaging,”
Clinical Nuclear Medicine, vol. 33, no. 3, pp. 208–210, 2008.
[14] M. Rodrigues, D. Westerman, S. Lade, C. McCormack, and
H. M. Prince, “Methotrexate-induced lymphoproliferative
disorder in a patient with S´ ezary syndrome,” Leukemia and
Lymphoma, vol. 47, no. 10, pp. 2257–2259, 2006.
[15] E. Salloum, D. L. Cooper, G. Howe, et al., “Sponta-
neous regression of lymphoproliferative disorders in patients
treated with methotrexate for rheumatoid arthritis and other
rheumatic diseases,” Journal of Clinical Oncology, vol. 14, no.
6, pp. 1943–1949, 1996.
[16] M. A. Waldman and J. P. Callen, “Self-resolution of Epstein-
Barr virus-associated B-cell lymphoma in a patient with der-
matomyositis following withdrawal of mycophenolate mofetil
and methotrexate,” Journal of the American Academy of
Dermatology, vol. 51, supplement 1, no. 2, pp. S124–S130,
2004.Case Reports in Medicine 5
[17] E. Baecklund, A. Iliadou, J. Askling, et al., “Association of
chronic inﬂammation, not its treatment, with increased lym-
phoma risk in rheumatoid arthritis,” Arthritis & Rheumatism,
vol. 54, no. 3, pp. 692–701, 2006.
[18] W.-Y. Au, E. S. K. Ma, C. Choy, et al., “Therapy-related lym-
phomas in patients with autoimmune diseases after treatment
withdisease-modifyinganti-rheumaticdrugs,”AmericanJour-
nal of Hematology, vol. 81, no. 1, pp. 5–11, 2006.
[19] R. K¨ uppers, “B cells under inﬂuence: transformation of B cells
byEpstein-Barrvirus,”NatureReviewsImmunology,vol.3,no.
10, pp. 801–812, 2003.
[20] W.-H. Feng, J. I. Cohen, S. Fischer, et al., “Reactivation
of latent Epstein-Barr virus by methotrexate: a potential
contributor to methotrexate-associated lymphomas,” Journal
of the National Cancer Institute, vol. 96, no. 22, pp. 1691–1702,
2004.